Blockade of the CD40-CD40L pathway with BI 655064 in rheumatoid arthritis patients with insufficient response to methotrexate-IR resulted in marked improvement in clinical and biological parameters (17,18), suggesting that the CD40-CD40L pathway might prove to be a target for novel therapeutic strategies for autoimmune diseases. This evidence concerns the gene CD40 and rheumatoid arthritis.